Medications

Trial results of new drug for generalized myasthenia gravis

Argenx, a Belgium pharmaceutical company, recently announced that The Lancet Neurology has published pivotal trial results from the Phase 3 ADAPT trial of efgartigimod, an FcRn antagonist, for the treatment of adults living ...

Diseases, Conditions, Syndromes

Guidelines developed for diagnosing, treating botulism

(HealthDay)—In new evidence-based clinical guidelines published in the May 7 issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report, recommendations are presented for diagnosing, ...

Immunology

Researchers discover new biomarker for rare autoimmune disease

University of Alberta researchers have identified a unique biological marker that can be used to identify the presence of the rare autoimmune disease myasthenia gravis, predict the course of the disease and identify new, ...

Diseases, Conditions, Syndromes

Researchers identify previously unknown bacterial strain

Clinicians at the Department of Neurology of MedUni Vienna/Vienna General Hospital identified muscle weakness and severe fatigue in a previously healthy patient, to the extent that he was soon confined to a wheelchair. These ...

Diseases, Conditions, Syndromes

Study explains why myasthenia patients relapse after treatment

A new Yale-led study helps explain why some myasthenia gravis (MG) patients relapse after initially responding to a drug called rituximab, commonly used to treat the incurable autoimmune disease marked by muscle weakness ...

Oncology & Cancer

New study supports surgery as treatment for myasthenia gravis

In a global study of myasthenia gravis, an autoimmune disease that causes muscle weakness and fatigue, researchers found that surgical removal of an organ called the thymus reduced patients' weakness, and their need for immunosuppressive ...

page 1 from 3